News event: 2026-10-22. Updated: October 26, 2026.
An experimental personalized mRNA treatment reduced the risk of melanoma returning or patients dying by 42% when combined with Keytruda, compared with Keytruda alone, according to Phase 3 results announced by Merck and Moderna on October 22. The finding offers encouraging evidence for individualized cancer immunotherapy, but the vaccine has not yet been approved for routine use.
What the trial found
The randomized INTerpath-001 study enrolled 1,137 people whose high-risk stage IIB–IV cutaneous melanoma had been surgically removed. After a median follow-up of 24.6 months, the combined treatment lowered the relative risk of recurrence or death by 42%. The companies also reported a 38% reduction in the risk of distant metastasis or death.
At two years, 82.2% of patients in the combination group remained free of recurrence, compared with 70.0% receiving Keytruda alone. Those percentages describe outcomes in this trial population; they do not mean the treatment cures 82% of melanoma patients. Overall survival data were not yet mature.
How the individualized approach works
The investigational treatment, called intismeran autogene, is designed using mutations identified in an individual patient’s tumor. Its mRNA instructs cells to produce selected tumor-related signals that may help the immune system recognize cancer cells. Keytruda is an existing immunotherapy that helps immune cells respond to tumors.
Merck said the safety profile was broadly consistent with earlier research and no new safety signals were identified. Side effects still matter, and the benefits and risks must be assessed by regulators using the full trial record.
The companies are discussing the results with regulators while additional follow-up continues. For patients, the key distinction is between promising clinical-trial evidence and an available treatment: this personalized mRNA therapy remains investigational.
Sources and verification
Featured image: original AI-generated conceptual illustration; not a photograph of the reported event.
Context matters. Read about our editorial standards and corrections policy.
Join the conversation